Venture Certified
| 연구개발유형 | 2019-06-12 ~ 2021-06-11 | 20190106386 | 2019-06-12 |
| 연구개발유형 | 2021-06-12 ~ 2024-06-11 | 20210721020040 | 2019-06-12 |
| 연구개발유형 | 2024-06-12 ~ 2027-06-11 | 20240724020004 | 2019-06-12 |
Revenue CAGR +62.9%
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 2.5B | 2.9B | 0.9B |
| Operating Profit | -4.6B | -1.9B | -4.4B |
| Net Profit | -4.6B | -1.9B | -4.3B |
| Total Assets | 7.5B | 2.8B | 2.3B |
| Total Liabilities | 1.4B | 1.9B | 3.4B |
| Total Equity | 6.1B | 0.9B | -1.1B |
Capital Erosion: Total equity is negative or below 50% of capital stock
Operating Loss: Op. profit -5B
3 Consecutive Years of Net Loss
▲ 30.0%
▼ 45.7%
▲ 31.1%
▲ 141.9%
▼ 180.1%
| Name | Position | Role |
|---|---|---|
| 유범호 | 대표이사 | 대표 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
1 Additional Data Sources
{
"address": "인천광역시 연수구",
"ceo_name": "유범호",
"certificate": [
{
"cert_number": "20190106386",
"changes": "",
"disclosure_date": "2019-06-12",
"first_cert_date": "2019-06-12",
"no": "1",
"type": "연구개발유형",
"valid_period": "2019-06-12 ~ 2021-06-11"
},
{
"cert_number": "20210721020040",
"changes": "",
"disclosure_date": "2021-07-21",
"first_cert_date": "2019-06-12",
"no": "2",
"type": "연구개발유형",
"valid_period": "2021-06-12 ~ 2024-06-11"
},
{
"cert_number": "20240724020004",
"changes": "",
"disclosure_date": "2024-07-24",
"first_cert_date": "2019-06-12",
"no": "3",
"type": "연구개발유형",
"valid_period": "2024-06-12 ~ 2027-06-11"
}
],
"company_name": "주식회사 휴젝스",
"corp_no": "131111-*******",
"financials": {
"2022": {
"capital_stock": 2419999000,
"cost_of_sales": 643000,
"current_assets": 81841000,
"current_liabilities": 342306000,
"gross_profit": 92312000,
"net_income": -429764000,
"net_income_bs": -429764000,
"non_current_assets": 151611000,
"non_current_liabilities": 0,
"non_operating_expenses": 160000,
"non_operating_income": 10018000,
"operating_profit": -439622000,
"revenue": 92955000,
"sga_expenses": 531934000,
"total_assets": 233452000,
"total_equity": -108854000,
"total_liabilities": 342306000
},
"2023": {
"capital_stock": 2459000000,
"cost_of_sales": 6188000,
"current_assets": 191464000,
"current_liabilities": 187170000,
"gross_profit": 280520000,
"net_income": -189326000,
"net_income_bs": -189326000,
"non_current_assets": 87907000,
"non_current_liabilities": 0,
"non_operating_expenses": 158000,
"non_operating_income": 65000,
"operating_profit": -189233000,
"revenue": 286708000,
"sga_expenses": 469753000,
"total_assets": 279371000,
"total_equity": 92201000,
"total_liabilities": 187170000
},
"2024": {
"capital_stock": 2569000000,
"cost_of_sales": 68925000,
"current_assets": 212140000,
"current_liabilities": 126095000,
"gross_profit": 177895000,
"net_income": -459609000,
"net_income_bs": -459609000,
"non_current_assets": 535134000,
"non_current_liabilities": 15256000,
"non_operating_expenses": 3874000,
"non_operating_income": 2519000,
"operating_profit": -458254000,
"revenue": 246820000,
"sga_expenses": 636149000,
"total_assets": 747274000,
"total_equity": 605923000,
"total_liabilities": 141351000
}
},
"industry": "물리, 화학 및 생물학 연구개발업",
"investment": [],
"main_products": "재조합 단백질, 의료 및 미용기기",
"phone": "032-858-****",
"years": [
2024,
2023,
2022
]
}